RTRaquel Tobes

Raquel Tobes

*This is an algorithmically generated author record based on publicly available information.

Raquel Tobes has a total of 203 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CD4 + tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts

    by Anaïs Jiménez-Reinoso, Magdalena Molero-Abraham, Cristina Cirauqui, Belén Blanco, Eva M. Garrido-Martin, Daniel Nehme-Álvarez, Carmen Domínguez-Alonso, Ángel Ramírez-Fernández, Laura Díez-Alonso, Ángel Nuñez-Buiza, et al.

    Adoptive transfer of tumor-infiltrating lymphocytes (TIL) has shown remarkable results in melanoma, but only modest clinical benefits in other cancers, even after TIL have been genetically modified to improve their tumor homing, cytotoxic potential or overcome cell exhaustion. The required ex vivo TIL expansion process may induce changes in the T cell clonal composition, which could likely compromise the tumor reactivity of TIL preparations and ultimately the success of TIL therapy. A promising approach based on the production of bispecific T cell-engagers (TCE) by engineered T cells (STAb-T therapy) improves the efficacy of current T cell redirection strategies against tumor-associated antigens in hematological tumors. We studied the TCRβ repertoire in non-small cell lung cancer (NSCLC) tumors and in ex vivo expanded TIL from two unrelated patients. We generated TIL secreting anti-epidermal growth factor receptor (EGFR) × anti-CD3 TCE (TILSTAb) and tested their antitumor efficacy in vitro and in vivo using a NSCLC patient-derived xenograft (PDX) model in which tumor fragments and TIL from the same patient were transplanted into hIL-2 NOG mice. We confirmed that the standard TIL expansion protocol promotes the loss of tumor-dominant T cell clones and the overgrowth of virus-reactive TCR clonotypes that were marginally detectable in primary tumors. We demonstrated the antitumor activity of TILSTAb both in vitro and in vivo when administered intratumorally and systemically in an autologous immune-humanized PDX EGFR+ NSCLC mouse model, where tumor regression was mediated by TCE-redirected CD4+ TIL bearing non-tumor dominant clonotypes.


  • Open Access

    CD4 + tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts

    by Anaïs Jiménez-Reinoso, Magdalena Molero-Abraham, Cristina Cirauqui, Belén Blanco, Eva M. Garrido-Martin, Daniel Nehme-Álvarez, Carmen Domínguez-Alonso, Ángel Ramírez-Fernández, Laura Díez-Alonso, Ángel Nuñez-Buiza, et al.

    Adoptive transfer of tumor-infiltrating lymphocytes (TIL) has shown remarkable results in melanoma, but only modest clinical benefit in other cancers, even after TIL have been genetically modified to improve their tumor homing, cytotoxic potential or overcoming cell exhaustion. The required ex vivo TIL expansion process may induce changes in the T cell clonal composition, which could likely compromise the tumor reactivity of TIL preparations and ultimately the success of TIL therapy. A promising approach based on the production of bispecific T cell engagers (TCE) by engineered T cells (STAb-T therapy) improves the efficacy of current T cell redirection strategies against tumor-associated antigens in hematological tumors. We studied the TCRβ repertoire in non-small cell lung cancer (NSCLC) tumors and in ex vivo expanded TIL from two unrelated patients. We generated TIL secreting anti-epidermal growth factor receptor (EGFR) x anti-CD3 TCE (TIL STAb ) and tested their antitumor efficacy in vitro and in vivo using a NSCLC patient-derived xenograft (PDX) model in which tumor fragments and TIL from the same patient were transplanted into hIL-2 NOG mice. We confirmed that the standard TIL expansion protocol promotes the loss of tumor-dominant T cell clones and the overgrowth of virus-reactive TCR clonotypes that were marginally detectable in primary tumors. We demonstrated the antitumor activity of TIL STAb both in vitro and in vivo when administered intratumorally and systemically in an autologous immune-humanized PDX EGFR + NSCLC mouse model, where tumor regression was mediated by TCE-redirected CD4 + TIL bearing non-tumor dominant clonotypes. SIGNIFICANCE: Epithelial tumor-derived TIL can be engineered to secrete TCE capable of redirecting T cells bearing non-tumor-dominant clonotypes regardless of their phenotype, which could have broad applications in immunotherapy for solid tumors.

  • Open Access

    Glyceraldehyde-3-phosphate Dehydrogenase Common Peptides of Listeria monocytogenes, Mycobacterium marinum and Streptococcus pneumoniae as Universal Vaccines

    by David Salcines-Cuevas, Hector Terán-Navarro, Ricardo Calderón-Gonzalez, Paula Torres-Rodriguez, Raquel Tobes, Manuel Fresno, Jorge Calvo-Montes, I. Concepción Pérez Del Molino-Bernal, Sonsoles Yañez-Diaz, Carmen Alvarez-Dominguez

    Universal vaccines can be prepared with antigens common to different pathogens. In this regard, the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a common virulence factor among pathogenic bacteria of the genera Listeria, Mycobacterium and Streptococcus. Their N-terminal 22 amino acid peptides, GAPDH-L1 (Listeria), GAPDH-M1 (Mycobacterium) and GAPDH-S1 (Streptococcus), share 95–98.55% sequence homology, biochemical and MHC binding abilities and, therefore, are good candidates for universal vaccine designs. Here, we used dendritic cells (DC) as vaccine platforms to test GAPDH epitopes that conferred protection against Listeria monocytogenes, Mycobacterium marinum or Streptococcus pneumoniae in our search of epitopes for universal vaccines. DC loaded with GAPDH-L1, GAPDH-M1 or GAPDH-S1 peptides show high immunogenicity measured by the cellular DTH responses in mice, lacked toxicity and were capable of cross-protection immunity against mice infections with each one of the pathogens. Vaccine efficiency correlated with high titers of anti-GAPDH-L1 antibodies in sera of vaccinated mice, a Th1 cytokine pattern and high frequencies of GAPDH-L1-specific CD4+ and CD8+ T cells and IFN-γ producers in the spleens. We concluded that GAPDH-L1 peptide was the best epitope for universal vaccines in the Listeria, Mycobacterium or Streptococcus taxonomic groups, whose pathogenic strains caused relevant morbidities in adults and especially in the elderly.


  • Pre-clinical development of Listeria-based nanovaccines as immunotherapies for solid tumours: insights from melanoma

    by Hector Terán-Navarro, Ricardo Calderon-Gonzalez, David Salcines-Cuevas, Isabel García, Marco Marradi, Javier Freire, Erwan Salmon, Mar Portillo-Gonzalez, Elisabet Frande-Cabanes, Almudena García-Castaño, et al.

    Gold glyconanoparticles loaded with the listeriolysin O peptide 91–99 (GNP-LLO91-99), a bacterial peptide with anti-metastatic properties, are vaccine delivery platforms facilitating immune cell targeting and increasing antigen loading. Here, we present proof of concept analyses for the consideration of GNP-LLO91-99 nanovaccines as a novel immunotherapy for cutaneous melanoma. Studies using mouse models of subcutaneous melanoma indicated that GNP-LLO91-99 nanovaccines recruite and modulate dendritic cell (DC) function within the tumour, alter tumour immunotolerance inducing melanoma-specific cytotoxic T cells, cause complete remission and improve survival. GNP-LLO91-99 nanovaccines showed superior tumour regression and survival benefits, when combined with anti-PD-1 or anti-CTLA-4 checkpoint inhibitors, resulting in an improvement in the efficacy of these immunotherapies. Studies on monocyte-derived DCs from patients with stage IA, IB or IIIB melanoma confirmed the ability of GNP-LLO91-99 nanovaccines to complement the action of checkpoint inhibitors, by not only reducing the expression of cell-death markers on DCs, but also potentiating DC antigen-presentation. We propose that GNP-LLO91-99 nanovaccines function as immune stimulators and immune effectors and serve as safe cancer therapies, alone or in combination with other immunotherapies.


  • Open Access

    Complete Genome Sequences of Isolates of Enterococcus faecium Sequence Type 117, a Globally Disseminated Multidrug-Resistant Clone

    by Ana P. Tedim, Val F. Lanza, Marina Manrique, Eduardo Pareja, Patricia Ruiz-Garbajosa, Rafael Cantón, Fernando Baquero, Teresa M. Coque, Raquel Tobes

    The emergence of nosocomial infections by multidrug-resistant sequence type 117 (ST117) Enterococcus faecium has been reported in several European countries. ST117 has been detected in Spanish hospitals as one of the main causes of bloodstream infections. We analyzed genome variations of ST117 strains isolated in Madrid and describe the first ST117 closed genome sequences.


  • Open Access

    Bacterial sequences detected in 99 out of 99 serum samples from Ebola patients

    by Marina Manrique, Eduardo Pareja-Tobes, Eduardo Pareja, Pablo Pareja-Tobes, Raquel Tobes

    Evolution and clinical manifestations of Ebola virus (EBOV) infection overlap with the pathologic processes that occur in sepsis 1 . Some viruses certainly compromise the immune system, leading to a breach in the integrity of the mucosal epithelial barrier, thus allowing bacterial translocation 2, 3 . Guided by these facts, we wondered if bacteria could be involved in the pathogenesis of some of the septic shock-like symptoms typical of EBOV infected patients, something that could have a dramatic impact on the design of new treatment approaches. We decided to search for bacteria in available EBOV patient sequence datasets. Given that EBOV is an RNA virus and that, hence, some NGS sequencing experiments carried out to sequence the EBOV genomes were RNA-Seq experiments, we thought that, if there were any bacteria in patient serum, at least some bacterial RNA might probably be detected in the sequenced material from Ebola patients. Thus, we searched for bacteria in a RNA-Seq public dataset from 99 Ebola samples from the last outbreak 4 , and surprisingly, in spite of the certainly suboptimal experimental conditions for bacterial RNA sequencing, we found bacteria in all of the 99 samples.


  • Open Access

    Expression of Early Growth Response Gene-2 and Regulated Cytokines Correlates with Recovery from Guillain–Barré Syndrome

    by Ernesto Doncel-Pérez, Lourdes Mateos-Hernández, Eduardo Pareja, Ángel García-Forcada, Margarita Villar, Raquel Tobes, Francisco Romero Ganuza, Virginia Vila del Sol, Ricardo Ramos, Isabel G. Fernández de Mera, et al.

    Guillain–Barré syndrome (GBS) is an immune-mediated peripheral neuropathy. The goal of this research was the identification of biomarkers associated with recovery from GBS. In this study, we compared the transcriptome of PBMCs from a GBS patient and her healthy twin to discover possible correlates of disease progression and recovery. The study was then extended using GBS and spinal cord injury unrelated patients with similar medications and healthy individuals. The early growth response gene-2 (EGR2) was upregulated in GBS patients during disease recovery. The results provided evidence for the implication of EGR2 in GBS and suggested a role for EGR2 in the regulation of IL-17, IL-22, IL-28A, and TNF-β cytokines in GBS patients. These results identified biomarkers associated with GBS recovery and suggested that EGR2 overexpression has a pivotal role in the downregulation of cytokines implicated in the pathophysiology of this acute neuropathy.


  • Open Access

    Integrated Metabolomics, Transcriptomics and Proteomics Identifies Metabolic Pathways Affected by Anaplasma phagocytophilum Infection in Tick Cells*

    by Margarita Villar, Nieves Ayllón, Pilar Alberdi, Andrés Moreno, María Moreno, Raquel Tobes, Lourdes Mateos-Hernández, Sabine Weisheit, Lesley Bell-Sakyi, José de la Fuente


  • Open Access

    Comparative Genomics of Field Isolates of Mycobacterium bovis and M. caprae Provides Evidence for Possible Correlates with Bacterial Viability and Virulence

    by José de la Fuente, Iratxe Díez-Delgado, Marinela Contreras, Joaquín Vicente, Alejandro Cabezas-Cruz, Raquel Tobes, Marina Manrique, Vladimir López, Beatriz Romero, Javier Bezos, et al.

    Mycobacteria of the Mycobacterium tuberculosis complex (MTBC) greatly affect humans and animals worldwide. The life cycle of mycobacteria is complex and the mechanisms resulting in pathogen infection and survival in host cells are not fully understood. Recently, comparative genomics analyses have provided new insights into the evolution and adaptation of the MTBC to survive inside the host. However, most of this information has been obtained using M. tuberculosis but not other members of the MTBC such as M. bovis and M. caprae. In this study, the genome of three M. bovis (MB1, MB3, MB4) and one M. caprae (MB2) field isolates with different lesion score, prevalence and host distribution phenotypes were sequenced. Genome sequence information was used for whole-genome and protein-targeted comparative genomics analysis with the aim of finding correlates with phenotypic variation with potential implications for tuberculosis (TB) disease risk assessment and control. At the whole-genome level the results of the first comparative genomics study of field isolates of M. bovis including M. caprae showed that as previously reported for M. tuberculosis, sequential chromosomal nucleotide substitutions were the main driver of the M. bovis genome evolution. The phylogenetic analysis provided a strong support for the M. bovis/M. caprae clade, but supported M. caprae as a separate species. The comparison of the MB1 and MB4 isolates revealed differences in genome sequence, including gene families that are important for bacterial infection and transmission, thus highlighting differences with functional implications between isolates otherwise classified with the same spoligotype. Strategic protein-targeted analysis using the ESX or type VII secretion system, proteins linking stress response with lipid metabolism, host T cell epitopes of mycobacteria, antigens and peptidoglycan assembly protein identified new genetic markers and candidate vaccine antigens that warrant further study to develop tools to evaluate risks for TB disease caused by M. bovis/M.caprae and for TB control in humans and animals. Mycobacteria belonging to the Mycobacterium tuberculosis complex infect humans and animals since pre-history and are a serious health problem worldwide. Whole-genome sequencing and comparative genomics generate information on the evolution and molecular basis of pathogenicity and transmissibility. However, while genomic information is increasingly available for the main human pathogens such as Mycobacterium tuberculosis, little is known about closely related bacteria, Mycobacterium bovis and Mycobacterium caprae. These mycobacteria infect humans causing zoonotic tuberculosis and are the main causative agents of animal tuberculosis. Although human-to-human transmission of zoonotic tuberculosis is limited, the infection often causes extra-pulmonary disease in humans and is still a major public health concern in developing countries, causing not only human disease but also severe effects on livelihoods. In this study, whole-genome sequences and targeted comparative genomics of three Mycobacterium bovis and one Mycobacterium caprae field isolates generated new information on the evolution and phenotypic variation of these mycobacteria. The results identified new genetic markers and candidate vaccine antigens that warrant further study to develop tools to evaluate risks for tuberculosis caused by M. bovis/M.caprae and for disease control in humans and animals.


  • Open Access

    MG7: Configurable and scalable 16S metagenomics data analysis

    by Alexey Alekhin, Evdokim Kovach, Marina Manrique, Pablo Pareja-Tobes, Eduardo Pareja, Raquel Tobes, Eduardo Pareja-Tobes

    As part of the Cambrian explosion of omics data, metagenomics brings to the table a specific, defining trait: its social essence. The meta prefix exerts its influence, with multitudes manifesting themselves everywhere; from samples to data analysis, from actors involved to (present and future) applications. Of these dimensions, data analysis is where needs lay further from what current tools provide. Key features are, among others, scalability, reproducibility, data provenance and distribution, process identity and versioning. These are the goals guiding our work in MG7, a 16S metagenomics data analysis system. The basic principle is a new approach to data analysis, where configuration, processes, or data locations are static, type-checked and subject to the standard evolution of a well-maintained software project. Cloud computing, in its Amazon Web Services incarnation, when coupled with these ideas, produces a robust, safely configurable, scalable tool. Processes, data, machine behaviors and their dependencies are expressed using a set of libraries which bring as much as possible checking and validation to the type level, without sacrificing expressiveness. Together they form a toolkit for defining scalable cloud-based workflows composed of stateless computations, with a static reproducible specification of dependencies, behavior and wiring of all steps. The modeling of taxonomy data is done using Bio4j, where the new paradigm of graph databases allows for both a simple expression of taxonomic assignment tasks and the calculation of taxa abundance values considering the hierarchic structure of the taxonomy tree. MG7 includes a new 16S reference database, 16S-DB7 , built with a flexible and sustainable update system, and the possibility of project-driven personalization.